Biglycan Appetite Suppression via Hypothalamic Peptide Modulation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current obesity treatments lack effective appetite suppressants that are safe and provide significant weight loss without adverse cardiovascular effects, with existing medications either having limited efficacy or causing complications.

Innovation Solution

A pharmaceutical composition containing biglycan, which inhibits the expression of appetite-promoting peptides and promotes the expression of appetite-suppressing peptides, thereby reducing food intake and body weight, is used to treat or prevent obesity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If existing appetite suppressants (Belviq, Qsymia) are used, then weight loss effect is improved, but side effects on cardiovascular system and brain increase

Engineering Contradiction:

Improveweight loss effectVSAvoidcardiovascular and brain side effects

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent uses biglycan, a naturally occurring proteoglycan with short half-life, as a temporary and safe appetite suppressant that does not accumulate in the body, avoiding long-term cardiovascular and brain side effects associated with conventional drugs like Qsymia

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

Biglycan acts as a natural intermediary substance that mediates appetite regulation by binding to and modulating neurotransmitters in the hypothalamus, providing a safer alternative to direct-acting synthetic appetite suppressants

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If Belviq is used, then safety is improved, but weight loss efficacy is reduced

Engineering Contradiction:

Improvesafety profileVSAvoidweight loss efficacy

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent modifies the mechanism of action by changing the molecular parameter of the appetite suppressant from synthetic compounds to biglycan, a natural proteoglycan with different binding characteristics that simultaneously achieves safety and enhanced weight loss efficacy through hypothalamic neurotransmitter modulation

Inventive Principle:

Principle #35Parameter changes

3Productivity

If Qsymia is used, then weight loss efficacy is improved, but cardiovascular complications increase

Engineering Contradiction:

Improveweight loss efficacyVSAvoidcardiovascular complications

Core Design Contradiction:

ProductivityVSObject-generated harmful factors

Solution Approach 1:

The patent converts the natural physiological role of biglycan in tissue maintenance into a therapeutic benefit for obesity treatment, utilizing its inherent ability to regulate appetite without the harmful cardiovascular effects of synthetic appetite suppressants

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS12048731B2Appetite suppression with pharmaceutical compositions containing biglycan as an active ingredient

Publication Date: 2024.07.30 KOREA UNIV RES & BUSINESS FOUND

AI summary

The present invention relates to a pharmaceutical composition which is for preventing or treating obesity, and comprises a biglycan as an active ingredient. Biglycan according to the present invention suppresses appetite by decreasing the expression of Agrp and NPY, which are appetite promoting peptides, and increasing the expression of POMC, which is an appetite suppressing peptide, and thus is very useful as a medicine for treating obesity.